Ozempic and similar drugs: miracle or health risk?
The FDA has issued a "black box" warning for Ozempic and Mounjaro due to the risk of thyroid tumors in rodents. While social media is flooded with tanned, well-lit "before and after" photos, excess skin folds and potential side effects are left out of the frame. The debate over these drugs goes beyond aesthetics: it touches on the medicalization of obesity, pharmacological dependence, and real alternatives.
The promise of rapid weight loss
Testimonials of losing 15 to 20 kilos in a few months are common. But so is weight regain upon discontinuing treatment. "As soon as she stopped injecting, she continued eating as before and returned to her previous size," one user notes. The drug reduces appetite but does not eliminate the need for emotional gratification through food. Those who stop treatment without changing habits regain the lost weight.
Risks that don't show up on Instagram
Safety warnings are serious: aside from possible thyroid cancer, effects such as loose skin, pancreatitis, and psychological dependence are mentioned. Some argue that "self-discipline and self-control" are preferable to "medications to ruin half of overweight people." However, others acknowledge that obesity is not just a matter of willpower, but involves factors like depression or addiction.
Competing alternatives
Against GLP-1 agonists, options emerge such as the strict carnivore diet, intermittent fasting, or even metformin, with which one user lost 8 kg in 6 months. The debate remains unresolved: while some defend the efficiency of the drugs, others distrust pharmaceutical companies' intentions and advocate for sustainable lifestyle changes.
The lingering question is whether these medications are a useful tool under medical supervision or a dangerous trend that creates dependence and fails to address the root causes of obesity.
Related forum discussions